In the interview given to BX1, our co-director, Michel Goldman, talks about the progress made in the fight against COVID-19, the unprecedented acceleration of the research process and possible issues with the production of sufficient quantities of the vaccine.
How to prevent and cure COVID-19?
Watch the recording of our conference-debate on the vaccines and immunotherapies at the forefront of the fight against the pandemic.
Antibody-based therapies for COVID-19: Can Europe move faster?
In the article published by PLOS, Michel Goldman, Michel Kazatchkine and Jean-Louis Vincent call on the medical and scientific European community to urgently coordinate research efforts on passive immunotherapy, share data and protocols in real-time, and pool efforts to decrease as much as possible the time for validating immunotherapy with donated plasma.
The development of therapeutic immune globulins and laboratory-made immune components to rapidly substitute to donated plasma needs to be accelerated.